Avalia Immunotherapies to advance immunotherapy technology
21 May 2015
An immunotherapy technology for treating cancer and other diseases, jointly developed by Victoria University of Wellington’s Ferrier Research Institute and the Malaghan Institute of Medical Research, has been patented and will be the initial focus of a newly-formed company, Avalia Immunotherapies.
The research has been led by Dr Gavin Painter from the Ferrier Research Institute and Dr Ian Hermans from the Malaghan Institute, and works as a therapeutic vaccine, activating a patient’s own immune system to recognise and attack cancer cells.
The director of the Ferrier Research Institute, Professor Richard Furneaux, says Avalia Immunotherapies will further develop the ground-breaking technology and aims to progress it to clinical trials.
For the full media release see http://www.victoria.ac.nz/news/2015/05/new-company-to-advance-potential-treatment-for-cancer-and-other-diseases